Dyadic Applied BioSolutions (NASDAQ: DYAI) shares advanced Monday. The Jupiter, Fla.-based company, a global biotechnology concern producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications today announced that it has entered into an original equipment manufacturer distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices, a life sciences reagent manufacturer and distributor serving global research markets. Through this collaboration, according to this morning’s news release,
Dyadic-produced recombinant protein products will be commercialized through IBT’s established sales channels, expanding market access and supporting Dyadic’s objective of generating ongoing, product-based revenues.”
The initial products expected to be offered under the agreement include recombinant DNase I and recombinant transferrin, with a focus on research-use-only applications. Dyadic expects to offer both human and bovine transferrin, along with additional cell culture–relevant recombinant proteins, as part of a broader and expanding product portfolio.
This relationship complements Dyadic’s recent portfolio and manufacturing expansion initiatives and supports the Company’s ability to commercialize a broader range of recombinant protein products across multiple end markets. By leveraging IBT’s established commercial infrastructure, Dyadic can efficiently place products into the market while continuing to scale manufacturing capabilities and broaden its offerings over time.
DYA shares began Monday acquired 6.5 cents, or 8.6%, to 82 cents.
Related Stories
